Ivey Business School (Canada)
-
Canadian Telecommunications: Industry Regulation and Policy
Adam Fremeth; Ken MarkCase IVEY-9B11M005-EStrategyThis case study is based on a high-profile issue facing the Canadian federal government that began in 2008 and was still ongoing as of December 2010. Industry Canada, working from a set of policy objectives crafted over a period of three years, had decided that in the auction sale of wireless spectrum licenses in 2008, it would set aside 40 per cent of the licenses for new entrants. This decision had come about because research indicated that Can...Starting at €8.20
-
The Canadian Television Industry Confronts Subscription Video on Demand
Adam Fremeth; Rod E. White; Kartik RaoCase IVEY-9B16M072-EStrategyIn late 2015, developments in the Canadian television industry led the incumbent players to reconsider their traditional distribution strategies. The conflux of changes to technology, regulatory reforms, and consumption patterns was complicated by the entry of new players, forcing established firms to consider revising their business models. The regulated oligopolistic industry structure that once protected the players and ensured superior perfor...Starting at €8.20
-
The Heat is ON
Mark Zbaracki; Maziar RazCase IVEY-9B14M097-EEntrepreneurship, StrategyIn January 2014, the chief executive officer of AutoTherm, a small smart-thermostat design company located in Toronto, Canada, was considering the company’s future in light of the uncertainties and fast changing dynamics of the industry. As an incumbent and small engineering firm, AutoTherm’s plans to sell its first product, B133, through partnership with a large electronics company had not been quite successful. Given the dire state of the compa...Starting at €8.20
-
Hoffmann-La Roche: Pricing the Zelboraf Melanoma Treatment for Canada
Mark Zbaracki; Jedy WangCase IVEY-9B16M138-EStrategyThe Canadian brand manager of Zelboraf had to decide how to introduce and price Zelboraf in the Canadian market. Zelboraf was a breakthrough discovery in treatment for melanoma cancer patients. Hoffmann-La Roche (Roche) began developing Zelboraf in 2005. During the clinical trials, the drug yielded such positive results in targeting late-stage (metastatic) melanoma cancer that Roche ended clinical trials early in order to expedite FDA approval an...Starting at €8.20
-
CanniMed Therapeutics Inc.: The IPO Dilemma
Adam Fremeth; Zhou Zhang; Dean PopilCase IVEY-W26387-EFinance, StrategyIn November 2016, the chief executive officer of CanniMed Therapeutics Inc. was considering the company’s options for raising capital through an initial public offering. The decision was critical for the Saskatchewan-based medical cannabis company, whichStarting at €8.20
-
Globalive: Change in the Canadian Wireless Telecom Industry
Adam Fremeth; Tony S. Frost; Guy L.F. Holburn; Kevin Chan; Peter WalkerCase IVEY-9B11M003-EEntrepreneurship, StrategyThis case describes the situation for Globalive in 2009 shortly after its bid to enter the Canadian wireless telecommunications sector had been denied by the regulatory agency on the grounds that it breached foreign ownership restrictions. The case covers the background to Globalive and the events leading to the regulator’s decision. Andrea Wood, the chief legal officer of WIND Mobile, the wireless brand owned by Globalive, must decide what recom...Starting at €8.20